REGULATORY

WED, Feb 10, 2020 09:00 CET

RLS GLOBAL AB (publ) INTERIM REPORT, YEAR-END REPORT 2020

OCTOBER 1st – DECEMBER 31th
  • Net sales amounted to KSEK 139 (KSEK 54)
  • Earnings before interest and taxes (EBIT) amounted to MSEK -7,2 (MSEK -8,9)
  • Earning per share before dilution at SEK -0,11 (SEK -0,15)
  • Cash flow from operating activities amounted to MSEK -7,0 (MSEK -5,7)
  • Liquid assets at the end of the period MSEK 18,9 (MSEK 41,7)
  • Equity ratio was 88 % (90 %)
JANUARY 1st – DECEMBER 31th
  • Net sales amounted to KSEK 2,043 (KSEK 1,023)
  • Earnings before interest and taxes (EBIT) amounted to MSEK -22,3 (MSEK -26,7)
  • Earnings before interest and taxes (EBIT) amounted to MSEK -22,3 (MSEK -26,7)
  • Cash flow from operating activities amounted to MSEK -22,2 (MSEK-24,9)
  • Liquid assets at the end of the period MSEK 18,9 (MSEK 41,7)
  • Equity ratio was 88 % (90 %)
SUMMARY OF EVENTS DURING FOURTH QUARTER
  • Continued focus on future regional/global cooperation.
  • RLS participated in EWMA, the European Wound Conference which this year was digital. Docent Jan Apelqvist presented an abstract from the ChloraSolv01 study.
  • A pre-study regarding automatic production has been conducted during fall.
  • New exciting results from tests performed in Lund.
SUMMARY OF EVENTS DURING THE YEAR
SUMMARY OF EVENTS DURING Q1
  • Redeye was appointed new Certified Adviser.
  • The immaterial rights regarding PeriSolv was sold to Regident AG.
  • RLS signed a contract with Region Kalmar län.
SUMMARY OF EVENTS DURING Q2
  • RLS signed contracts with Region Stockholm/Gotland.
  • Increased use of ChloraSolv in Region Kalmar län.
SUMMARY OF EVENTS DURING Q3
  • ChloraSolv approved in Canada.
  • RLS signed contract with Region Skåne.
  • Recurrent sales of ChloraSolv.
SUMMARY OF EVENTS AFTER FOURTH QUARTER
  • RLS Global was audited by Eurofins and Lloyds (notified bodies) with very good result.
COVID-19
  • In the current situation, the Board has considered the impact of different possible future covid-19 related scenarios.
  • Since the healthcare sector is so extremely strained under the prevailing circumstances, all processes take longer which affects our market penetration and other activities, resulting in RLS focusing even more on R&D projects.
TRADING PLACE AND CERTIFIED ADVISER

RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag.
phone: +46 8 121 576 90, email: certifiedadviser@redeye.se.
During the period 2012–2017, the company was listed on Aktietorget.

CONTACT INFORMATION

Karin Fischer, CEO
E-mail: karin.fischer@rlsglobal.se
Telephone: +46 702-48 46 51

Eva Jagenheim, CFO
E-mail: eva.jagenheim@rlsglobal.se
Telephone: +46 31 780 68 20

PUBLICATION

This information was submitted for publication through the agency of the above contact person, at 09.00 CET on February 10th, 2021.

RLS GLOBAL AB (publ) YEAR-END REPORT 2020